Our study demonstrates that DATS disrupts glycolytic metabolism in breast cancer cells, as evidenced by a significant reduction in glucose uptake, downregulation of key glycolytic regulators (GLUT1, LDHA, and HIF1α), and diminished lactate production following combination treatment with DOX. The gene discussed is HIF1A; the disease is breast carcinoma.